Smoking and Crohn's Disease: How to Quit and Why It Helps

A lot of us were handed a Crohn's diagnosis and a stack of leaflets about diet, biologics and surgery, and nobody ever mentioned cigarettes. If that was your experience, you are not alone, and this is not a lecture. Smoking and Crohn's disease have one of the most consistently measured relationships in IBD research: what smoking does to flares and surgery, what changes for people who quit, and which quit methods have strong trial evidence behind them.

Key Takeaways

• Across 33 observational studies, smokers with Crohn's had higher odds of a disease flare, OR 1.56 (95% CI 1.21 to 2.01), and of needing a first surgery, OR 1.68 (95% CI 1.33 to 2.12) (2).
• The odds of needing a second surgery were roughly doubled in smokers, OR 2.17 (95% CI 1.63 to 2.89) (2).
• In the same review, ex-smokers' odds of flare and surgery fell after quitting to levels comparable to people who had never smoked (2).
• In a 4-year prospective study, continuing smokers relapsed earlier whether or not they were on an anti-TNF or an immunosuppressant, so being on a biologic does not cancel the effect (3).
• A Cochrane network meta-analysis of 319 randomized trials found varenicline roughly doubles quit rates, OR 2.33 (95% CrI 2.02 to 2.68), and that a patch plus a fast-acting nicotine product beats a patch alone (4).
• This applies to Crohn's disease. The well-known finding that smoking tracks differently with ulcerative colitis points in the opposite direction and is never a reason for anyone to smoke (1).

How Smoking Is Linked to Crohn's Disease

Smoking is associated with a higher chance of developing Crohn's disease in the first place. A meta-analysis of nine studies found current smoking carried an odds ratio of 1.76 (95% CI 1.40 to 2.22) for developing Crohn's compared with not smoking (1). An umbrella review of meta-analyses placed smoking among the environmental factors linked to Crohn's risk with high to moderate credibility. These are observational associations, not proof that one thing causes the other.

The risk of developing Crohn's

An odds ratio of 1.76 is a population-level signal, and it does not mean smoking caused your Crohn's. Plenty of people with Crohn's have never touched a cigarette, and plenty of lifelong smokers never develop it. What it tells researchers is that tobacco keeps showing up across different populations and study designs, which is why it is taken seriously as the one major Crohn's risk factor that can actually be changed.

If you are reading this after a recent diagnosis and doing arithmetic about the years you smoked, please stop there. Nothing here is about assigning blame for a disease you did not choose. The useful part of this research is not about the past.

What we do not know about the mechanism

Here is something many articles gloss over: the biological mechanism linking tobacco to Crohn's disease is not settled. Researchers have proposed explanations, but we are not going to describe a pathway as though it were established fact, because in the sources behind this article it is not.

That uncertainty does not weaken the clinical picture. The associations with flares, surgery and relapse have been measured repeatedly and consistently, and they stand on their own regardless of whether the biology is fully explained yet.

What Smoking Does to Your Disease Course

For people who already have Crohn's, smoking is associated with a measurably rougher course. In a systematic review of 33 observational studies, smokers compared with nonsmokers had higher odds of a flare of disease activity, OR 1.56 (95% CI 1.21 to 2.01), higher odds of needing a first surgery, OR 1.68 (95% CI 1.33 to 2.12), and higher odds of needing a second surgery, OR 2.17 (95% CI 1.63 to 2.89) (2). These are observational studies, which matters for how much weight they carry.

Flares

If you are newly diagnosed and the word flare is still new, our guide to understanding flares and remission in Crohn's disease explains what counts as one and how remission is defined. An OR of 1.56 for flare in smokers is a real difference in day-to-day life, not a statistical curiosity.

The same review also found higher odds of a flare after surgery in smokers, OR 1.97 (95% CI 1.36 to 2.85) (2). We cover that picture separately in our article on preventing postoperative Crohn's recurrence.

Surgery and repeat surgery

The surgery numbers tend to land hardest. Odds of a first surgery raised by roughly two thirds, and odds of a second surgery roughly doubled (2). For background on when and why surgery enters the picture at all, see our overview of the role of surgery in Crohn's disease management. Bear in mind that an odds ratio describes a group, not a prediction for one person: many smokers with Crohn's never have surgery.

Does this still hold in the biologic era?

This is the fair question, and someone has studied it. A 4-year prospective study followed 573 Crohn's patients in remission at enrollment: 148 continuing smokers, 190 nonsmokers, 160 former smokers and 75 who quit during the study (3).

Continuing smokers relapsed more often than nonsmokers, incidence rate ratio 1.53 (95% CI 1.10 to 2.17), and smoking was an independent predictor of relapse, hazard ratio 1.58 (95% CI 1.20 to 2.09) (3). Crucially, they relapsed earlier regardless of whether they were taking an anti-TNF or an immunosuppressant (3). Modern therapy did not neutralise the effect, and that is the finding most worth carrying out of this section.

What Actually Changes When You Quit

This is the part of the evidence that gives the article its reason to exist. In the 33-study review, the odds of flare and surgery among ex-smokers diminished after cessation, becoming comparable to people who had never smoked, and for flare and for second surgery they were significantly lower than in people who kept smoking (2).

Quitters end up looking like nonsmokers

The prospective study points the same way. Of the 573 patients followed, the 75 who quit during the study had relapse rates similar to the 190 nonsmokers, while the 148 who kept smoking did worse (3). Two study designs, two populations, the same place.

In our community, this is the finding people most often say they wish someone had told them years earlier. Not "smoking is bad for you," which everybody already knows, but the specific idea that the Crohn's-related difference appears to narrow for people who stop.

How strong is this evidence?

We want to be straight about what kind of evidence this is. These are observational cohorts and a meta-analysis of observational studies. Nobody has run a randomized trial assigning people with Crohn's to quit or keep smoking, and for obvious ethical reasons nobody will.

Observational data can be influenced by differences between the people who quit and the people who do not. The signal here is consistent and reasonably large, which is why it is taken seriously, but it is not the same grade of evidence as a randomized drug trial. Quitting is associated with a better disease course. What nobody can promise you is remission, a cure, or a specific percentage of improvement as an individual.

The Ulcerative Colitis Myth, and Why It Does Not Apply to Crohn's

Sooner or later someone in an IBD group will say that smoking helps inflammatory bowel disease. There is a real finding underneath that claim, and it concerns ulcerative colitis, not Crohn's. The same meta-analysis that found smoking raised the odds of developing Crohn's found that current smoking was associated with lower odds of developing ulcerative colitis, OR 0.58 (95% CI 0.45 to 0.75), while former smoking was associated with higher odds of UC, OR 1.79 (95% CI 1.37 to 2.34) (1).

Where the idea came from

Those are population-level associations about the risk of developing ulcerative colitis. They are not treatment advice, they were not produced by a trial of smoking as therapy, and they point in the opposite direction from everything measured in Crohn's. Two conditions often lumped together as IBD behave differently here, which is a reminder that the distinction matters clinically. If you are not certain which diagnosis you have, our comparison of Crohn's disease versus ulcerative colitis covers the differences.

Why it is still not a reason to smoke

To say it as plainly as we can: nothing in this research is a reason for anyone with Crohn's disease to start smoking or keep smoking. The Crohn's-specific findings run the other way, and the general health harms of tobacco, from cardiovascular disease to cancer, are not in dispute and are not changed by having IBD.

Quit Methods With the Strongest Evidence

If quitting is the lever, it helps to know which methods have real evidence behind them. A Cochrane component network meta-analysis pooled 319 randomized trials and 157,179 participants and ranked the options (4). One caveat before the numbers: this review studied general adult smokers, not people with IBD, so treat it as the best available evidence on quitting rather than as anything Crohn's-specific.

Prescription options

The review found high-certainty evidence that varenicline roughly doubles quit rates compared with control, OR 2.33 (95% CrI 2.02 to 2.68), which works out to roughly 8 extra quitters per 100 people (95% CrI 6 to 10) (4). Cytisine performed similarly, OR 2.21 (95% CrI 1.66 to 2.97), and bupropion came in lower at OR 1.43 (95% CrI 1.26 to 1.62) (4). Note that these are credibility intervals, which is the Bayesian equivalent of the confidence intervals quoted earlier in this article.

Varenicline, cytisine and bupropion are prescription medicines and availability differs considerably between countries. They are a conversation with a clinician, not a self-service option, and your own doctor is the person to weigh them against your history and current Crohn's treatment.

Nicotine replacement, alone and in combination

The most practical finding concerns how nicotine replacement is used. Combination nicotine replacement, meaning a patch plus a fast-acting form such as gum or a lozenge, had a calculated additive OR of 1.93 (95% CrI 1.61 to 2.34), while a patch alone came in at OR 1.37 (95% CrI 1.20 to 1.56) and fast-acting nicotine replacement alone at OR 1.41 (95% CrI 1.29 to 1.55) (4).

The combination clearly outperformed either piece on its own. If you have tried a patch before and it did not hold, that is useful information rather than evidence that you cannot quit: the patch alone is one of the weaker options here.

On safety, serious adverse event rates across these treatments were low, averaging 3%, with no clear difference compared with placebo for most options, although bupropion may slightly increase them (4).

Where e-cigarettes sit

The same review found high-certainty evidence that nicotine e-cigarettes produced higher quit rates than control, OR 2.37 (95% CrI 1.73 to 3.24) (4). That is what the trials showed for quitting smoking.

What we cannot tell you is what vaping does in Crohn's disease specifically, because the sources behind this article contain no Crohn's-specific safety data on e-cigarettes. Please do not read that odds ratio as us calling vaping safe for your gut, or as an IBD-specific recommendation. The Crohn's question is simply unanswered here.

Building a Quit Plan With Your IBD Team

Here is the uncomfortable part, and we would rather you hear it from us than discover it yourself. A 2023 systematic review found only 5 published studies of smoking cessation interventions designed for people with Crohn's disease, with samples ranging from 17 to 474 participants. Abstinence ranged from 14.8% to 42%, was 25% or lower in four of the five studies, and the three studies with control groups did not show significantly higher quit rates in the intervention arms (5).

Why generic advice often is not enough

Read that correctly. It is a small, limited evidence base about program design, and its authors called for tailored cessation programs for Crohn's patients to be developed and properly evaluated (5). It is not evidence that quitting does not help, which is a separate question answered by the cohort data earlier in this article.

The practical conclusion: do not wait for an IBD-specific quit program, and do not rely on a one-off mention at a gastroenterology appointment. The treatments with high-certainty randomized evidence behind them are the general ones, and they are worth using as a real medical intervention rather than a side note.

Free support you can use today

In the United States, the CDC points to several free options: calling 1-800-QUIT-NOW (1-800-784-8669) for free phone coaching, texting QUITNOW to 333888, and the quitSTART app (6). The CDC also lists the nicotine patch, lozenge, gum, oral inhaler and nasal spray, along with varenicline and bupropion SR, as options, and says that making a quit plan is the first step (6).

Readers outside the US will have different quitlines and different rules about which of these medicines are available or reimbursed. The underlying structure, coaching plus medication rather than willpower alone, travels.

What to ask your gastroenterologist

Three concrete asks turn a vague intention into a plan. Ask for a referral to a cessation service rather than a general suggestion to stop. Ask whether a prescription option such as varenicline or bupropion is appropriate for you, given your other medicines and history. And if surgery is being planned or discussed, ask whether quitting should be prioritised beforehand, given what the data show about first and repeat operations (2).

If relapse happens, and for many people it does more than once, that is not a failure and not a reason to stop trying. Coming back to it is part of how this works.

What This Means in Practice

Smoking is the single most modifiable factor in the course of Crohn's disease, and the evidence says people who quit tend to end up looking like people who never smoked, at least in terms of flare and surgery odds (2)(3). Being on a biologic does not take that effect off the table (3). The methods with the best randomized evidence are prescription medicines and combination nicotine replacement, not a patch on its own (4), and the free coaching infrastructure already exists while a Crohn's-specific program does not (5)(6). Bring it to your next appointment as a treatment decision, because that is what it is.

Frequently Asked Questions

Does smoking actually make Crohn's disease worse?

The observational evidence consistently points that way. Across 33 studies, smokers with Crohn's had higher odds of a flare, OR 1.56 (95% CI 1.21 to 2.01), of a first surgery, OR 1.68 (95% CI 1.33 to 2.12), and of a second surgery, OR 2.17 (95% CI 1.63 to 2.89) (2). A 4-year prospective study found smoking was an independent predictor of relapse, hazard ratio 1.58 (95% CI 1.20 to 2.09) (3).

How quickly do things improve after I quit?

The studies report outcomes over years rather than weeks, so there is no timeline we can honestly give you. They show that ex-smokers' odds of flare and surgery diminished after cessation to levels comparable to people who never smoked (2), and that in a 4-year cohort the 75 patients who quit had relapse rates similar to the 190 nonsmokers (3). These are group averages from observational data, not a promise about your next few months.

I am on a biologic. Does that cancel out the smoking risk?

No. In the 4-year prospective study, continuing smokers relapsed earlier regardless of whether they were on an anti-TNF or an immunosuppressant (3), which is precisely why the authors looked at current treatment algorithms. Your biologic is doing its job, and quitting is a separate lever rather than a redundant one.

Is it true that smoking protects against ulcerative colitis?

There is a real association, and it concerns UC rather than Crohn's. Current smoking was associated with lower odds of developing ulcerative colitis, OR 0.58 (95% CI 0.45 to 0.75), while former smoking was associated with higher odds, OR 1.79 (95% CI 1.37 to 2.34) (1). Those describe who develops UC in populations, they are not treatment advice, and they run opposite to the Crohn's findings. Nothing there is a reason for someone with Crohn's to smoke.

What is the most effective way to quit?

In a Cochrane review of 319 randomized trials and 157,179 general adult participants, varenicline had the strongest result, OR 2.33 (95% CrI 2.02 to 2.68), followed by cytisine, OR 2.21 (95% CrI 1.66 to 2.97), and combination nicotine replacement, OR 1.93 (95% CrI 1.61 to 2.34) (4). A patch on its own was weaker, OR 1.37 (4). These were not measured in IBD populations.

Is vaping a safe alternative if I have Crohn's?

We cannot tell you that. Nicotine e-cigarettes did show higher quit rates than control in the Cochrane review, OR 2.37 (95% CrI 1.73 to 3.24) (4), but that is a general-population finding about quitting smoking. The sources behind this article contain no Crohn's-specific safety data on vaping, so treat it as an open question for your own clinician.

Are there quit programs designed specifically for Crohn's patients?

Very few, and they have not yet been shown to beat standard care. A 2023 systematic review found only 5 published studies, with abstinence from 14.8% to 42%, 25% or lower in four of them, and no significantly higher quit rates in the intervention arms of the three controlled studies (5). The authors called for tailored programs to be developed and evaluated. Until then, the general cessation treatments with randomized evidence behind them are the better bet.

References

1. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic Proceedings, 2006;81(11):1462-1471. View on PubMed
2. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016;43(5):549-561. View on PubMed
3. Nunes T, Etchevers MJ, Garcia-Sanchez V, et al. Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study. American Journal of Gastroenterology, 2016;111(3):411-419. View on PubMed
4. Lindson N, Theodoulou A, Ordonez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database of Systematic Reviews, 2023;9(9):CD015226. View on PubMed
5. Nasr S, Nsiri I, Fredj MB. Effectiveness of smoking cessation interventions for smokers with Crohn's disease: a systematic review. Future Science OA, 2023;9(7):FSO870. View on PubMed
6. Centers for Disease Control and Prevention. Quit Smoking, Tips From Former Smokers. Last reviewed September 27, 2024. Read guide